{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T17:55:15Z","timestamp":1794333315828,"version":"4.9.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,31]],"date-time":"2020-07-31T00:00:00Z","timestamp":1596153600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,31]],"date-time":"2020-07-31T00:00:00Z","timestamp":1596153600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["JR19\/00025"],"award-info":[{"award-number":["JR19\/00025"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"UK National Institute of Health Research","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Citizens affected by substance use disorders are high-risk populations for both SARS-CoV-2 infection and COVID-19-related mortality. Relevant vulnerabilities to COVID-19 in people who suffer substance use disorders are described in previous communications. The COVID-19 pandemic offers a unique opportunity to reshape and update addiction treatment networks.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Main body<\/jats:title>\n<jats:p>Renewed treatment systems should be based on these seven pillars: (1) telemedicine and digital solutions, (2) hospitalization at home, (3) consultation-liaison psychiatric and addiction services, (4) harm-reduction facilities, (5) person-centered care, (6) promote paid work to improve quality of life in people with substance use disorders, and (7) integrated addiction care. The three \u201cbest buys\u201d of the World Health Organization (reduce availability, increase prices, and a ban on advertising) are still valid. Additionally, new strategies must be implemented to systematically deal with (a) fake news concerning legal and illegal drugs and (b) controversial scientific information.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>The heroin pandemic four decades ago was the last time that addiction treatment systems were updated in many western countries. A revised and modernized addiction treatment network must include improved access to care, facilitated where appropriate by technology; more integrated care with addiction specialists supporting non-specialists; and reducing the stigma experienced by people with SUDs.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12916-020-01693-9","type":"journal-article","created":{"date-parts":[[2020,7,31]],"date-time":"2020-07-31T01:02:57Z","timestamp":1596157377000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["\u201cThe post-COVID era\u201d: challenges in the treatment of substance use disorder (SUD) after the pandemic"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3850-8374","authenticated-orcid":false,"given":"Hugo","family":"L\u00f3pez-Pelayo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henri-Jean","family":"Aubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Drummond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert","family":"Dom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Pascual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Rehm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Saitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Scafato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoni","family":"Gual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,31]]},"reference":[{"key":"1693_CR1","unstructured":"World Health Organisation. WHO Response in Countries. https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/donate\/who-response-in-countries. Accessed 4 May 2020."},{"key":"1693_CR2","doi-asserted-by":"publisher","unstructured":"Miyara M, Tubach F, POURCHER V, Morelot-Panzini C, Pernet J, Haroche J, et al. Low incidence of daily active tobacco smoking in patients with symptomatic COVID-19. Qeios. 2020. doi:https:\/\/doi.org\/10.32388\/WPP19W.3.","DOI":"10.32388\/WPP19W.3"},{"key":"1693_CR3","doi-asserted-by":"publisher","unstructured":"Vardavas C, Nikitara K. COVID-19 and smoking: a systematic review of the evidence. Tob Induc Dis. 2020;18 March. doi:https:\/\/doi.org\/10.18332\/tid\/119324.","DOI":"10.18332\/tid\/119324"},{"key":"1693_CR4","doi-asserted-by":"publisher","unstructured":"Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Cardiovascular disease, drug therapy, and mortality in covid-19. N Engl J Med. 2020;:NEJMoa2007621. doi:https:\/\/doi.org\/10.1056\/NEJMoa2007621.","DOI":"10.1056\/NEJMoa2007621"},{"key":"1693_CR5","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1111\/add.13757","volume":"112","author":"J Rehm","year":"2017","unstructured":"Rehm J, Gmel GE, Gmel G, Hasan OSM, Imtiaz S, Popova S, et al. The relationship between different dimensions of alcohol use and the burden of disease\u2014an update. Addiction. 2017;112:968\u20131001.","journal-title":"Addiction."},{"key":"1693_CR6","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.chest.2017.11.041","volume":"154","author":"E Simou","year":"2018","unstructured":"Simou E, Leonardi-Bee J, Britton J. The effect of alcohol consumption on the risk of ARDS: a systematic review and meta-analysis. Chest. 2018;154:58\u201368.","journal-title":"Chest."},{"key":"1693_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.euroneuro.2020.02.003","volume":"33","author":"E Campeny","year":"2020","unstructured":"Campeny E, L\u00f3pez-Pelayo H, Nutt D, Blithikioti C, Oliveras C, Nu\u00f1o L, et al. The blind men and the elephant: systematic review of systematic reviews of cannabis use related health harms. Eur Neuropsychopharmacol. 2020;33:1\u201335.","journal-title":"Eur Neuropsychopharmacol"},{"key":"1693_CR8","doi-asserted-by":"publisher","unstructured":"Volkow ND. Collision of the COVID-19 and addiction epidemics. Ann Intern Med. 2020. https:\/\/doi.org\/10.7326\/M20-1212.","DOI":"10.7326\/M20-1212"},{"key":"1693_CR9","volume-title":"COVID-19 and the drug supply chain: from production and trafficking to use","author":"UNODC","year":"2020","unstructured":"UNODC. COVID-19 and the drug supply chain: from production and trafficking to use. 2020. www.unodc.org. Accessed 8 May 2020."},{"key":"1693_CR10","doi-asserted-by":"publisher","unstructured":"Vieta E, P\u00e9rez V, Arango C. LA PSIQUIATR\u00cdA EN LAS SECUELAS DE COVID-19. Rev Psiquiatr Salud Ment. 2020. https:\/\/doi.org\/10.1016\/j.rpsm.2020.04.004.","DOI":"10.1016\/j.rpsm.2020.04.004"},{"key":"1693_CR11","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1089\/tmj.2013.0370","volume":"21","author":"S Schmidt-Weitmann","year":"2015","unstructured":"Schmidt-Weitmann S, B\u00f6sch S, Weidt S, Brockes C. Psychological online consultation service attracts men: a new approach to close the gap between being ill and being treated. Telemed J E Health. 2015;21:48\u201354. https:\/\/doi.org\/10.1089\/tmj.2013.0370.","journal-title":"Telemed J E Health"},{"key":"1693_CR12","volume-title":"Access to Telehealth","author":"American Society of Addiction Medicine","year":"2020","unstructured":"American Society of Addiction Medicine. Access to Telehealth. 2020. https:\/\/www.asam.org\/Quality-Science\/covid-19-coronavirus\/access-to-telehealth. Accessed 10 Jun 2020."},{"key":"1693_CR13","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1056\/NEJMp2003539","volume":"382","author":"JE Hollander","year":"2020","unstructured":"Hollander JE, Carr BG. Virtually perfect? Telemedicine for covid-19. N Engl J Med. 2020;382:1679\u201381. https:\/\/doi.org\/10.1056\/NEJMp2003539.","journal-title":"N Engl J Med"},{"key":"1693_CR14","unstructured":"EMCDDA. EMCDDA publishes update on the implications of COVID-19 for people who use drugs and for drug service providers | www.emcdda.europa.eu. http:\/\/www.emcdda.europa.eu\/news\/2020\/emcdda-publishes-update-on-the-implications-of-COVID-19-for-people-who-use-drugs-and-for-drug-service-providers_en. Accessed 4 May 2020."},{"key":"1693_CR15","unstructured":"Government of Canada. Exemptions for practitioners and pharmacists prescribing and providing controlled substances, and for patients, during the coronavirus pandemic - Canada.ca. https:\/\/www.canada.ca\/en\/health-canada\/services\/health-concerns\/controlled-substances-precursor-chemicals\/policy-regulations\/policy-documents\/section-56-1-class-exemption-patients-pharmacists-practitioners-controlled-substances-covid-19-pandemic.html. Accessed 4 May 2020."},{"key":"1693_CR16","doi-asserted-by":"publisher","unstructured":"Gupta M, Abdelmaksoud A, Jafferany M, Lotti T, Sadoughifar R, Goldust M. COVID-19 and economy. Dermatol Ther. 2020:e13329. https:\/\/doi.org\/10.1111\/dth.13329.","DOI":"10.1111\/dth.13329"},{"key":"1693_CR17","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.socscimed.2015.02.025","volume":"131","author":"MCM de Goeij","year":"2015","unstructured":"de Goeij MCM, Suhrcke M, Toffolutti V, van de Mheen D, Schoenmakers TM, Kunst AE. How economic crises affect alcohol consumption and alcohol-related health problems: a realist systematic review. Soc Sci Med. 2015;131:131\u201346.","journal-title":"Soc Sci Med"},{"key":"1693_CR18","doi-asserted-by":"publisher","DOI":"10.1093\/acprof:oso\/9780198714002.003.0008","volume-title":"Impact of the economic recession on addiction-prone behaviours","author":"A Dubanowicz","year":"2015","unstructured":"Dubanowicz A, Lemmens P. Impact of the economic recession on addiction-prone behaviours; 2015."},{"key":"1693_CR19","doi-asserted-by":"publisher","unstructured":"Rehm J, Kilian C, Ferreira-Borges C, Jernigan D, Monteiro M, Parry CDH, et al. Alcohol use in times of the COVID 19: Implications for monitoring and policy. Drug Alcohol Rev. 2020;:dar.13074. doi:https:\/\/doi.org\/10.1111\/dar.13074.","DOI":"10.1111\/dar.13074"},{"key":"1693_CR20","doi-asserted-by":"publisher","unstructured":"Dom G, Samochowiec J, Evans-Lacko S, Wahlbeck K, Van Hal G, McDaid D. The impact of the 2008 economic crisis on substance use patterns in the countries of the European Union. Int J Environ Res Public Health. 2016;13(1):122. https:\/\/doi.org\/10.3390\/ijerph13010122.","DOI":"10.3390\/ijerph13010122"},{"key":"1693_CR21","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.4088\/JCP.10m06019gry","volume":"72","author":"KL Chou","year":"2011","unstructured":"Chou KL, Liang K, Sareen J. The association between social isolation and DSM-IV mood, anxiety, and substance use disorders: wave 2 of the national epidemiologic survey on alcohol and related conditions. J Clin Psychiatry. 2011;72:1468\u201376.","journal-title":"J Clin Psychiatry"},{"key":"1693_CR22","doi-asserted-by":"publisher","first-page":"4","DOI":"10.2174\/1874473711104010004","volume":"4","author":"D Henkel","year":"2011","unstructured":"Henkel D. Unemployment and substance use: a review of the literature (1990-2010). Curr Drug Abuse Rev. 2011;4:4\u201327.","journal-title":"Curr Drug Abuse Rev"},{"key":"1693_CR23","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.socscimed.2017.01.001","volume":"175","author":"JM Boden","year":"2017","unstructured":"Boden JM, Lee JO, Horwood LJ, Grest CV, McLeod GFH. Modelling possible causality in the associations between unemployment, cannabis use, and alcohol misuse. Soc Sci Med. 2017;175:127\u201334.","journal-title":"Soc Sci Med"},{"key":"1693_CR24","unstructured":"European Monitoring Centre for Drugs and Drug Addiction. EU Drug Markets \u2014 Impact of COVID-19 | www.emcdda.europa.eu. https:\/\/www.emcdda.europa.eu\/publications\/joint-publications\/eu-drug-markets-impact-of-covid-19. Accessed 10 Jun 2020."},{"key":"1693_CR25","unstructured":"Garc\u00eda C. Espa\u00f1a, \u00fanico gran pa\u00eds europeo que reabrir\u00e1 los bares antes que los colegios. Vozpopuli. https:\/\/www.vozpopuli.com\/espana\/Espana-Europa-apertura-bares-colegios-desescalada_0_1353165897.html. Accessed 10 Jun 2020."},{"key":"1693_CR26","unstructured":"ConFAc. ConFac | Confederaci\u00f3n de federaciones de Asociaciones Cann\u00e1bicas. https:\/\/confac.org\/. Accessed 10 Jun 2020."},{"key":"1693_CR27","unstructured":"IWSR. How the US beverage alcohol industry is responding to the COVID-19 crisis \u2013 IWSR. https:\/\/www.theiwsr.com\/how-the-us-beverage-alcohol-industry-is-responding-to-the-covid-19-crisis\/. Accessed 4 May 2020."},{"key":"1693_CR28","unstructured":"Smith RA, Pancevski B. Happy Hour Gets Earlier in Lockdown - WSJ. Wall Street J. 2020. https:\/\/www.wsj.com\/articles\/happy-hour-comes-nearly-every-day-for-social-drinkers-as-coronavirus-keeps-them-home-11588004362. Accessed 4 May 2020."},{"key":"1693_CR29","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s00406-016-0681-x","volume":"266","author":"M Martin-Carrasco","year":"2016","unstructured":"Martin-Carrasco M, Evans-Lacko S, Dom G, Christodoulou NG, Samochowiec J, Gonz\u00e1lez-Fraile E, et al. EPA guidance on mental health and economic crises in Europe. Eur Arch Psychiatry Clin Neurosci. 2016;266:89\u2013124.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"1693_CR30","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1056\/NEJMp1917360","volume":"382","author":"ND Volkow","year":"2020","unstructured":"Volkow ND. Stigma and the toll of addiction. N Engl J Med. 2020;382:1289\u201390. https:\/\/doi.org\/10.1056\/NEJMp1917360.","journal-title":"N Engl J Med"},{"key":"1693_CR31","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/S0140-6736(20)30460-8","volume":"395","author":"SK Brooks","year":"2020","unstructured":"Brooks SK, Webster RK, Smith LE, Woodland L, Wessely S, Greenberg N, et al. The psychological impact of quarantine and how to reduce it: rapid review of the evidence. Lancet. 2020;395:912\u201320.","journal-title":"Lancet"},{"key":"1693_CR32","doi-asserted-by":"publisher","unstructured":"Drummond C. Cuts to addiction services are a false economy. BMJ (Online). 2017;357:j2704. https:\/\/doi.org\/10.1136\/bmj.j2704.","DOI":"10.1136\/bmj.j2704"},{"key":"1693_CR33","doi-asserted-by":"publisher","first-page":"e13252","DOI":"10.2196\/13252","volume":"22","author":"CS Kruse","year":"2020","unstructured":"Kruse CS, Lee K, Watson JB, Lobo LG, Stoppelmoor AG, Oyibo SE. Measures of effectiveness, efficiency, and quality of telemedicine in the management of alcohol abuse, addiction, and rehabilitation: systematic review. J Med Internet Res. 2020;22:e13252.","journal-title":"J Med Internet Res"},{"key":"1693_CR34","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1159\/000445716","volume":"22","author":"E Hoch","year":"2016","unstructured":"Hoch E, Preuss UW, Ferri M, Simon R. Digital interventions for problematic cannabis users in non-clinical settings: findings from a systematic review and meta-analysis. Eur Addict Res. 2016;22:233\u201342. https:\/\/doi.org\/10.1159\/000445716.","journal-title":"Eur Addict Res"},{"key":"1693_CR35","doi-asserted-by":"publisher","first-page":"CD011479","DOI":"10.1002\/14651858.CD011479.pub2","volume":"9","author":"EF Kaner","year":"2017","unstructured":"Kaner EF, Beyer FR, Garnett C, Crane D, Brown J, Muirhead C, et al. Personalised digital interventions for reducing hazardous and harmful alcohol consumption in community-dwelling populations. Cochrane Database Syst Rev. 2017;9:CD011479. https:\/\/doi.org\/10.1002\/14651858.CD011479.pub2.","journal-title":"Cochrane Database Syst Rev"},{"key":"1693_CR36","doi-asserted-by":"publisher","unstructured":"Molfenter T, Brown R, O\u2019Neill A, Kopetsky E, Toy A. Use of telemedicine in addiction treatment: current practices and organizational implementation characteristics. Int J Telemed Appl. 2018;2018(Article ID 3932643):7 pages https:\/\/doi.org\/10.1155\/2018\/3932643.","DOI":"10.1155\/2018\/3932643"},{"key":"1693_CR37","doi-asserted-by":"publisher","unstructured":"Barney A, Buckelew S, Mesheriakova V, Raymond-Flesch M. The COVID-19 pandemic and rapid implementation of adolescent and young adult telemedicine: challenges and opportunities for innovation. J Adolesc Health. 2020. https:\/\/doi.org\/10.1016\/j.jadohealth.2020.05.006.","DOI":"10.1016\/j.jadohealth.2020.05.006"},{"key":"1693_CR38","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1016\/S0140-6736(20)31210-1","volume":"395","author":"The COVID-19 APHP Group","year":"2020","unstructured":"The COVID-19 APHP Group. Assistance Publique\u2013H\u00f4pitaux de Paris\u2019 response to the COVID-19 pandemic. Lancet. 2020;395:1760\u20131.","journal-title":"Lancet"},{"key":"1693_CR39","doi-asserted-by":"publisher","unstructured":"Ferreri F, Bourla A, Mouchabac S, Karila L e-Addictology: an overview of new technologies for assessing and intervening in addictive behaviors front psychiatry 2018;9:51. doi:https:\/\/doi.org\/10.3389\/fpsyt.2018.00051.","DOI":"10.3389\/fpsyt.2018.00051"},{"key":"1693_CR40","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.2105\/AJPH.2018.304571","volume":"108","author":"M Paris","year":"2018","unstructured":"Paris M, Silva M, A\u00f1ez-Nava L, Jaramillo Y, Kiluk BD, Gordon MA, et al. Culturally adapted, web-based cognitive behavioral therapy for Spanish-speaking individuals with substance use disorders: a randomized clinical trial. Am J Public Health. 2018;108:1535\u201342. https:\/\/doi.org\/10.2105\/AJPH.2018.304571.","journal-title":"Am J Public Health"},{"key":"1693_CR41","doi-asserted-by":"publisher","unstructured":"Delaigue S, Bonnardot L, Steichen O, Garcia DM, Venugopal R, Saint-Sauveur JF, et al. Seven years of telemedicine in Medecins Sans Frontieres demonstrate that offering direct specialist expertise in the frontline brings clinical and educational value. J Glob Health. 2018;8(2):020414. https:\/\/doi.org\/10.7189\/jogh.08.020414.","DOI":"10.7189\/jogh.08.020414"},{"key":"1693_CR42","unstructured":"NHS. Crisis resolution and intensive home treatment team (CRHT), urgent care services - Tees Esk and Wear Valleys NHS Foundation Trust. International Labour Office. 2020. https:\/\/www.tewv.nhs.uk\/services\/crisis-and-intensive-home-treatment-team\/. Accessed 10 Jun 2020."},{"key":"1693_CR43","unstructured":"Substance Abuse and Mental Health Services Administration. Chapter 4. Services in Intensive Outpatient Treatment Programs - Substance Abuse: Clinical Issues in Intensive Outpatient Treatment - NCBI Bookshelf. In: Substance Abuse: Clinical Issues in Intensive Outpatient Treatment. 2006. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK64094\/. Accessed 10 Jun 2020."},{"key":"1693_CR44","doi-asserted-by":"publisher","unstructured":"Cornelis J, Barakat A, Dekker J, Schut T, Berk S, Nusselder H, et al. Intensive home treatment for patients in acute psychiatric crisis situations: a multicentre randomized controlled trial. BMC Psychiatry. 2018;18(55). https:\/\/doi.org\/10.1186\/s12888-018-1632-z.","DOI":"10.1186\/s12888-018-1632-z"},{"key":"1693_CR45","doi-asserted-by":"publisher","unstructured":"Vieta E, P\u00e9rez V, Arango C. Psychiatry in the aftermath of COVID-19. Rev Psiquiatr Salud Ment. 2020. https:\/\/doi.org\/10.1016\/j.rpsm.2020.04.004. In press.","DOI":"10.1016\/j.rpsm.2020.04.004"},{"key":"1693_CR46","doi-asserted-by":"publisher","unstructured":"Gon\u00e7alves-Bradley DC, Iliffe S, Doll HA, Broad J, Gladman J, Langhorne P, et al. Early discharge hospital at home. Cochrane Database Syst Rev. 2017;6(6):CD000356. https:\/\/doi.org\/10.1002\/14651858.CD000356.pub4.","DOI":"10.1002\/14651858.CD000356.pub4"},{"key":"1693_CR47","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.rpsm.2018.09.003","volume":"12","author":"L Alba Pal\u00e9","year":"2019","unstructured":"Alba Pal\u00e9 L, Le\u00f3n Caballero J, C\u00f3rcoles Mart\u00ednez D, Gonz\u00e1lez Fresnedo AM, Bellsol\u00e0 Gonzalez M, Mart\u00edn L\u00f3pez LM, et al. Psychiatric Home Hospitalization Unit of the Hospital del Mar. A crisis resolution and home treatment team in Barcelona. Rev Psiquiatr Salud Ment. 2019;12:207\u201312.","journal-title":"Rev Psiquiatr Salud Ment."},{"key":"1693_CR48","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.eurpsy.2015.01.009","volume":"30","author":"I Boege","year":"2015","unstructured":"Boege I, Corpus N, Schepker R, Kilian R, Fegert JM. Cost-effectiveness of intensive home treatment enhanced by inpatient treatment elements in child and adolescent psychiatry in Germany: a randomised trial. Eur Psychiatry. 2015;30:583\u20139. https:\/\/doi.org\/10.1016\/j.eurpsy.2015.01.009.","journal-title":"Eur Psychiatry"},{"key":"1693_CR49","doi-asserted-by":"publisher","unstructured":"Bellis MA, Hughes K, Nicholls J, Sheron N, Gilmore I, Jones L. The alcohol harm paradox: using a national survey to explore how alcohol may disproportionately impact health in deprived individuals. BMC Public Health. 2016;16:111. https:\/\/doi.org\/10.1186\/s12889-016-2766-x.","DOI":"10.1186\/s12889-016-2766-x"},{"key":"1693_CR50","doi-asserted-by":"publisher","unstructured":"Algren MH, Bak CK, Berg-Beckhoff G, Andersen PT. Health-risk behaviour in deprived neighbourhoods compared with non-deprived neighbourhoods: a systematic literature review of quantitative observational studies. PLoS One. 2015;10(10):e0139297. https:\/\/doi.org\/10.1371\/journal.pone.0139297. eCollection 2015.","DOI":"10.1371\/journal.pone.0139297"},{"key":"1693_CR51","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.drugalcdep.2017.12.043","volume":"186","author":"CD Nordeck","year":"2018","unstructured":"Nordeck CD, Welsh C, Schwartz RP, Mitchell SG, Cohen A, O\u2019Grady KE, et al. Rehospitalization and substance use disorder (SUD) treatment entry among patients seen by a hospital SUD consultation-liaison service. Drug Alcohol Depend. 2018;186:23\u20138. https:\/\/doi.org\/10.1016\/j.drugalcdep.2017.12.043.","journal-title":"Drug Alcohol Depend"},{"key":"1693_CR52","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/J.JPSYCHORES.2018.11.020","volume":"116","author":"H L\u00f3pez-Pelayo","year":"2019","unstructured":"L\u00f3pez-Pelayo H, Miquel L, Altamirano J, Bataller R, Caballeria J, Ortega L, et al. Treatment retention in a specialized alcohol programme after an episode of alcoholic hepatitis: impact on alcohol relapse. J Psychosom Res. 2019;116:75\u201382. https:\/\/doi.org\/10.1016\/J.JPSYCHORES.2018.11.020.","journal-title":"J Psychosom Res"},{"key":"1693_CR53","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1111\/acer.14018","volume":"43","author":"K Witkiewitz","year":"2019","unstructured":"Witkiewitz K, Falk DE, Litten RZ, Hasin DS, Kranzler HR, Mann KF, et al. Maintenance of World Health Organization risk drinking level reductions and posttreatment functioning following a large alcohol use disorder clinical trial. Alcohol Clin Exp Res. 2019;43:979\u201387. https:\/\/doi.org\/10.1111\/acer.14018.","journal-title":"Alcohol Clin Exp Res"},{"key":"1693_CR54","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1111\/adb.12414","volume":"22","author":"K Charlet","year":"2017","unstructured":"Charlet K, Heinz A. Harm reduction\u2014a systematic review on effects of alcohol reduction on physical and mental symptoms. Addict Biol. 2017;22:1119\u201359.","journal-title":"Addict Biol"},{"key":"1693_CR55","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1136\/jech-2018-210981","volume":"73","author":"AJ Baxter","year":"2019","unstructured":"Baxter AJ, Tweed EJ, Katikireddi SV, Thomson H. Effects of Housing First approaches on health and well-being of adults who are homeless or at risk of homelessness: systematic review and meta-analysis of randomised controlled trials. J Epidemiol Community Health. 2019;73:379\u201387.","journal-title":"J Epidemiol Community Health"},{"key":"1693_CR56","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1037\/adb0000318","volume":"31","author":"CC DiClemente","year":"2017","unstructured":"DiClemente CC, Corno CM, Graydon MM, Wiprovnick AE, Knoblach DJ. Motivational interviewing, enhancement, and brief interventions over the last decade: a review of reviews of efficacy and effectiveness. Psychol Addict Behav. 2017;31:862\u201387. https:\/\/doi.org\/10.1037\/adb0000318.","journal-title":"Psychol Addict Behav"},{"key":"1693_CR57","doi-asserted-by":"publisher","first-page":"e0145817","DOI":"10.1371\/journal.pone.0145817","volume":"11","author":"A Friedrichs","year":"2016","unstructured":"Friedrichs A, Spies M, H\u00e4rter M, Buchholz A. Patient preferences and shared decision making in the treatment of substance use disorders: a systematic review of the literature. PLoS One. 2016;11:e0145817. https:\/\/doi.org\/10.1371\/journal.pone.0145817.","journal-title":"PLoS One"},{"key":"1693_CR58","doi-asserted-by":"publisher","unstructured":"Bush P, Drake R, Xie H, McHugo G, Haslett W. The long-term impact of employment on mental health service use and costs for persons with severe mental illness. Psychiatr Serv. 2009;60(8):1024\u201331. https:\/\/doi.org\/10.1176\/ps.2009.60.8.1024.","DOI":"10.1176\/ps.2009.60.8.1024"},{"key":"1693_CR59","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1176\/appi.ps.201500343","volume":"67","author":"A Luciano","year":"2016","unstructured":"Luciano A, Metcalfe JD, Bond GR, Xie H, Miller AL, Riley J, et al. Hospitalization risk before and after employment among adults with schizophrenia, bipolar disorder, or major depression. Psychiatr Serv. 2016;67:1131\u20138. https:\/\/doi.org\/10.1176\/appi.ps.201500343.","journal-title":"Psychiatr Serv"},{"key":"1693_CR60","unstructured":"UNSDG. UNSDG | Shared responsibility, global solidarity: Responding to the socio-economic impacts of COVID-19. https:\/\/unsdg.un.org\/resources\/shared-responsibility-global-solidarity-responding-socio-economic-impacts-covid-19. Accessed 4 May 2020."},{"key":"1693_CR61","unstructured":"International Labour Office. ILO: COVID-19 causes devastating losses in working hours and employment. 2020. https:\/\/www.ilo.org\/global\/about-the-ilo\/newsroom\/news\/WCMS_740893\/lang%2D%2Den\/index.htm. Accessed 10 Jun 2020."},{"key":"1693_CR62","doi-asserted-by":"publisher","first-page":"514","DOI":"10.15288\/jsad.2018.79.514","volume":"79","author":"D Chisholm","year":"2018","unstructured":"Chisholm D, Moro D, Bertram M, Pretorius C, Gmel G, Shield K, et al. Are the \u201cbest buys\u201d for alcohol control still valid? An update on the comparative cost-effectiveness of alcohol control strategies at the global level. J Stud Alcohol Drugs. 2018;79:514\u201322.","journal-title":"J Stud Alcohol Drugs"},{"key":"1693_CR63","unstructured":"SAMSHA. Coronavirus (COVID-19). 2020. https:\/\/www.samhsa.gov\/coronavirus. Accessed 10 Jun 2020."},{"key":"1693_CR64","unstructured":"European Monitoring Centre for Drugs and Drug Addiction. EMCDDA update on the implications of COVID-19 for people who use drugs and drug service providers | www.emcdda.europa.eu. 2020. https:\/\/www.emcdda.europa.eu\/publications\/topic-overviews\/catalogue\/covid-19-and-people-who-use-drugs_en. Accessed 10 Jun 2020."},{"key":"1693_CR65","unstructured":"American Society of Addiction Medicine. COVID-19 Coronavirus. 2020. https:\/\/www.asam.org\/Quality-Science\/covid-19-coronavirus. Accessed 16 Jun 2020."}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-020-01693-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-020-01693-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-020-01693-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T23:47:43Z","timestamp":1627688863000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-020-01693-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,31]]},"references-count":65,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1693"],"URL":"https:\/\/doi.org\/10.1186\/s12916-020-01693-9","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,31]]},"assertion":[{"value":"15 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Pascual received research grants (Camurus) and lectures\/training programs (Lundbeck, Gilead, Abbvie, Neuraxpharm, Pfizer).Dr. Aubin reported being a member of advisory boards or DSMB for Bioprojet, CV Sciences, and Ethypharm, and has received sponsorship to attend scientific meetings, speaker honoraria, or consultancy fees from Bioprojet, D&A Pharma, Ethypharm, Kinnov Pharmaceuticals, and Lundbeck. He is also a member of the American Society of Clinical Psychopharmacology\u2019s Alcohol Clinical Trials Initiative (ACTIVE), which was supported in the last 3\u00a0years by Alkermes, Amygdala Neurosciences, Arbor Pharmaceuticals, Ethypharm, Indivior, Lundbeck, Mitsubishi, and Otsuka.Dr. Gual received a grant from Novartis for a trial on cocaine that ended in April 2020.Dr. L\u00f3pez-Pelayo received training grants (Exeltis, Lundbeck).Dr. Saitz declares that Alkermes provides medication to Boston University for a trial supported by the US National Institutes of Health for which Dr. Saitz is the principal investigator. Dr. Saitz consults for various non-profit institutions and universities as a lecturer, expert, researcher, and editor in the area of addiction. He is the Editor-in-Chief of <i>Journal of Addiction Medicine<\/i> and the President of International Society of Addiction Journal Editors. He is an investigator for studies supported by the National Institutes of Health and faculty for a training program supported by the Burroughs Wellcome Foundation.Dr. Dom is a member of the scientific advisory board of Janssen-Cilag NV, Belgium.None of the previous conflicts of interest has relationship with this work.Others authors do not report any conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"241"}}